The ZLATÝ MOST II study was a multicenter randomized clinical trial that tested the effectiveness of a clinical decision support system (CDSS) with artificial intelligence in the treatment of acute ischemic stroke in 77 hospitals in China[1]. 21,603 patients (11,054 in the intervention group and 10,549 in the control group) were included in the study from January 2021 to June 2023[1]. The CDSS system provided AI analysis of images, classification of stroke causes, and evidence-based treatment recommendations[1]. The primary outcome was the occurrence of new vascular events (ischemic or hemorrhagic stroke, myocardial infarction or vascular death) within three months of symptom onset[1]. New vascular events occurred in 2.9% of patients in the intervention group versus 3.5% in the control group (adjusted hazard ratio 0.74, P=0.01)[1]. Patients in the intervention group also had a higher composite measure of quality of care (91.4% vs. 89.8%, P<0.001) and a lower incidence of new vascular events at 12 months (4.0% vs. 5.5%, P=0.02)[1]. The study found no significant differences in disability, mortality, or bleeding complications between the groups[1].